Table 2. Microorganisms isolated from prostate-specific specimens and per-pathogen eradication data in Cipro-500a and Cipro-750b treatment groups.
| Isolated organism (at time point V0) | Total isolates at baseline (V0), n | Eradication at the end of therapy, n (%) | Persistence at the end of therapy, n (%) | |||
|---|---|---|---|---|---|---|
| Cipro-500 | Cipro-750 | Cipro-500 | Cipro-750 | Cipro-500 | Cipro-750 | |
| Gram-negative | ||||||
| Escherichia coli | 34 | 23 | 20 (58.8) | 16 (69.6) | 14 (41.2) | 7 (30.4) |
| Haemophilus parainfluenzae | 12 | 5 | 9 (75.0) | 4 (80.0) | 3 (25.0) | 1 (20.0) |
| Proteus mirabilis | 7 | 4 | 6 (85.7) | 4 (100) | 1 (14.3) | — |
| Morganella morganii | 4 | 4 | 4 (100) | 4 (100) | — | — |
| Pseudomonas aeruginosa | 2 | — | 2 (100) | — | — | — |
| Klebsiella pneumoniae | 3 | 1 | 3 (100) | 1 (100) | — | — |
| Gardnerella vaginalis | 3 | — | 3 (100) | — | — | — |
| Enterobacter aerogenes | 2 | 1 | 2 (100) | 1 (100) | — | — |
| Klebsiella oxytoca | 2 | 3 | 1 (50.0) | 3 (100) | 1 (50.0) | — |
| Citrobacter koseri | 3 | 1 | 3 (100) | 1 (100) | — | — |
| Citrobacter freundii | 2 | 1 | 2 (100) | 1 (100) | — | — |
| Enterobacter cloacae | 2 | — | 1 (50.0) | — | 1 (50.0) | — |
| Enterobacter spp. | — | 1 | — | 1 (100) | — | — |
| Klebsiella ornithinolytica | — | 1 | — | 1 (100) | — | — |
| Serratia marcescens | — | 1 | — | 1 (100) | — | — |
| Gram-positive | ||||||
| Enterococcus faecalis | 46 | 28 | 24 (52.2) | 22 (78.6)c | 22 (47.8) | 6 (21.4) |
| Streptococcus spp. | 37 | 14 | 32 (86.5) | 13 (92.8) | 5 (13.5) | 1 (7.1) |
| Corynebacterium seminale | 7 | — | 6 (85.7) | — | 1 (14.3) | — |
| Staphylococcus haemolyticus | 2 | — | 2 (100) | — | — | — |
| Staphylococcus aureus | 2 | 1 | 2 (100) | 1 (100) | — | — |
| Neisseria gonorrhoeae | 1 | 1 | 1 (100) | 1 (100) | — | — |
| Corynebacterium species | 2 | 1 | 2 (100) | 1 (100) | — | — |
| Enterococcus spp. | 2 | 3 | 2 (100) | 3 (100) | — | — |
| Staphylococcus coag. neg. | — | 8 | — | 7 (87.5) | — | 1 (12.5) |
| Other | ||||||
| Ureaplasma urealyticum | 35 | 10 | 34 (97.1) | 10 (100) | 1 (2.9) | — |
| Mycoplasma hominis | 4 | — | 4 (100) | — | — | — |
| Candida spp. | 6 | 2 | 6 (100) | 2 (100) | — | — |
a
A cohort of patients treated with once-daily 500-mg ciprofloxacin for 6 weeks.
b
A cohort of patients treated with once-daily 750-mg ciprofloxacin for 4 weeks.
c
χ2=5.15, P=0.023, vs. Cipro-500 cohort.